Evidence map›Paper›PMID 25355482›Full record

GuidelineClinical toxicology (Philadelphia, Pa.)2014

Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Marc Ghannoum, Christopher Yates, Tais F Galvao, Kevin M Sowinski, Thi Hai Vân Vo, Andrew Coogan, Sophie Gosselin, Valery Lavergne, Thomas D Nolin, Robert S Hoffman and 1 more

Open access · bronzeAbstract readPractice GuidelineSystematic Review
In one paragraph

Guideline in Clinical toxicology (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Prevalence and Outcomes of Carbamazepine Toxicity in the Emergency Department: A Single-center Retrospective Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Hemoperfusion in the intensive care unit.Intensive care medicine · 2022
    Review
  17. Article
  18. Two cases of ceftriaxone-induced encephalopathy treated by hemoperfusion in hemodialysis patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

Marc GhannoumDivision of Nephrology, Verdun Hospital, University of Montreal , Montreal, QC , Canada.
Christopher Yates
Tais F Galvao
Kevin M Sowinski
Thi Hai Vân Vo
Andrew Coogan
Sophie Gosselin
Valery Lavergne
Thomas D Nolin
Robert S Hoffman
EXTRIP workgroup
Université de Montréal · CAHôpital du Sacré-Cœur de Montréal · CAHospital Universitario Son Espases · ESIndian Health Service · USMcGill University Health Centre · CANew York University · USPurdue University West Lafayette · USUniversidade Federal do Amazonas · BRUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe Extracorporeal Treatments in Poisoning (EXTRIP) workgroup was created to provide evidence and consensus-based recommendations on the use of extracorporeal treatments (ECTRs) in poisoning.

objectivesTo perform a systematic review and provide clinical recommendations for ECTR in carbamazepine poisoning.

methodsAfter a systematic literature search, the subgroup extracted the data and summarized the findings following a pre-determined format. The entire workgroup voted via a two-round modified Delphi method to reach a consensus on voting statements, using a RAND/UCLA Appropriateness Method to quantify disagreement. Anonymous votes were compiled, returned, and discussed in person. A second vote determined the final recommendations.

resultsSeventy-four articles met inclusion criteria. Articles included case reports, case series, descriptive cohorts, pharmacokinetic studies, and in-vitro studies; two poor-quality observational studies were identified, yielding a very low quality of evidence for all recommendations. Data on 173 patients, including 6 fatalities, were reviewed. The workgroup concluded that carbamazepine is moderately dialyzable and made the following recommendations: ECTR is suggested in severe carbamazepine poisoning (2D). ECTR is recommended if multiple seizures occur and are refractory to treatment (1D), or if life-threatening dysrhythmias occur (1D). ECTR is suggested if prolonged coma or respiratory depression requiring mechanical ventilation are present (2D) or if significant toxicity persists, particularly when carbamazepine concentrations rise or remain elevated, despite using multiple-dose activated charcoal (MDAC) and supportive measures (2D). ECTR should be continued until clinical improvement is apparent (1D) or the serum carbamazepine concentration is below 10 mg/L (42 the μ in μmol/L looks weird.) (2D). Intermittent hemodialysis is the preferred ECTR (1D), but both intermittent hemoperfusion (1D) or continuous renal replacement therapies (3D) are alternatives if hemodialysis is not available. MDAC therapy should be continued during ECTR (1D).

conclusionDespite the low quality of the available clinical evidence and the high protein binding capacity of carbamazepine, the workgroup suggested extracorporeal removal in cases of severe carbamazepine poisoning.

Indexed as

HemoperfusionRenal DialysisAdolescentAdultAnticonvulsantsCarbamazepineChildChild, PreschoolConsensusDelphi TechniqueDrug OverdoseEvidence-Based MedicineFemaleHumansInfantMaleAnticonvulsantsCarbamazepineAnticonvulsantHemodialysisHemoperfusionOverdose

Identifiers

PMID25355482
PMCPMC4782683
OpenAlexW3151776770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.